# US 6,726,908 B2 · Pharmaceutical formulation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,726,908 B2
- Document ID: US6726908B2
- Status: Granted
- Kind: B2
- Application number: 08/722,259
- Filed: 1997-10-27
- Published: 2001-11-22
- Granted: 2004-04-27
- Earliest claimed: 1995-09-07
- Assignees: SmithKline Beecham Corporation
- Inventors: Daniel Joseph Burch
- Web page: https://patentgrep.com/patent/US6726908B2

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2059: {Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin}
- A61K 31/397: having four-membered rings, e.g. azetidine
- A61K 31/424: condensed with heterocyclic ring systems, e.g. clavulanic acid
- A61K 31/43: Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula [IMAGE cpc-sch-A61K-0952.gif], e.g. penicillins, penems
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 27/16: Otologicals
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention relates to pharmaceutical formulations comprising amoxycillin and a salt clavulanic acid in a ratio of 14:1.

## Claims

### Claim 1

A method for the empiric treatment of infections potentially caused by DRSP in a human patient in need thereof, comprising the oral administration to said patient of a pharmaceutical formulation comprising amoxycillin and clavulanate in which the dosage amount is from 90±10% mg/kg of amoxycillin per day and 6.4±10% mg/kg of clavulanate per day, said dosage amount being administered in divided doses twice daily.

### Claim 2 (depends on 1)

The method according to claim 1 in which the dosage amount is 90±5% mg/kg of amoxycillin per day and 6.4±5% mg/kg of clavulanate per day.

### Claim 3 (depends on 2)

The method according to claim 2 in which the dosage amount is about 90 mg/kg of amoxycillin per day and about 6.4 mg/kg of clavulanate per day.

### Claim 4 (depends on 1, 2)

The method according to any one of claims 1, 2, or 3 wherein the amoxycillin is amoxycillin trihydrate and the clavulanate is potassium clavulanate.

### Claim 5 (depends on 4)

The method according to claim 4 wherein the patient is a pediatric patient.

### Claim 6 (depends on 1)

The method according to claim 1 wherein the formulation is a tablet, or a powder or granular product for reconstitution.

### Claim 7 (depends on 1)

The method according to claim 1 wherein the formulation is a liquid aqueous syrup or suspension.

### Claim 8

A method of treating otitis media in a patient in need thereof which comprises administering to said patient a pharmaceutical formulation comprising a dosage amount of 90±10% mg/kg of amoxycillin per day and 6.4±10% mg/kg of clavulanate per day, said dosage amount being administered in divided doses twice daily.

### Claim 9 (depends on 8)

The method according to claim 8 in which the dosage amount is 90±5% mg/kg of amoxycillin per day and 6.4±5% mg/kg of clavulanate per day.

### Claim 10 (depends on 9)

The method according to claim 9 in which the dosage amount is about 90 mg/kg of amoxycillin per day and about 6.4 mg/kg of clavulanate per day.

### Claim 11 (depends on 8, 9)

The method according to any one of claims 8, 9, or 10 wherein the amoxycillin is amoxycillin trihydrate and the clavulanate is potassium clavulanate.

### Claim 12 (depends on 11)

The method according to claim 11 wherein the patient is a pediatric patient.

### Claim 13 (depends on 8)

The method according to claim 8 wherein the formulation is a tablet, or a powder or granular product for reconstitution.

### Claim 14 (depends on 8)

The method according to claim 8 wherein the formulation is a liquid aqueous syrup or suspension.

### Claim 15

A method of treating sinusitis in a patient in need thereof which comprises administering to said patient a pharmaceutical formulation comprising a dosage amount of 90±10% mg/kg of amoxycillin per day and from 6.4±10% mg/kg of clavulanate per day, said dosage amount being administered in divided doses twice daily.

### Claim 16 (depends on 15)

The method according to claim 15 in which the dosage amount is 90±5% mg/kg of amoxycillin per day and 6.4±5% mg/kg of clavulanate per day.

### Claim 17 (depends on 16)

The method according to claim 16 in which the dosage amount is about 90 mg/kg of amoxycillin per day and about 6.4 mg/kg of clavulanate per day.

### Claim 18 (depends on 15, 16)

The method according to any one of claims 15, 16, or 17 wherein the amoxycillin is amoxycillin trihydrate and the clavulanate is potassium clavulanate.

### Claim 19 (depends on 18)

The method according to claim 18 wherein the patient is a pediatric patient.

### Claim 20 (depends on 15)

The method according to claim 15 wherein the formulation is a tablet, or a powder or granular product for reconstitution.

### Claim 21 (depends on 15)

The method according to claim 15 wherein the formulation is a liquid aqueous syrup or suspension.

### Claim 22

A method of treating a respiratory infection in a patient in need thereof, which comprises administering to said patient a pharmaceutical formulation comprising a dosage amount of 90±10% mg/kg of amoxycillin per day and 6.4±10% mg/kg of clavulanate per day, said dosage amount being administered in divided doses twice daily.

### Claim 23 (depends on 22)

The method according to claim 22 in which the dosage amount is 90±5% mg/kg of amoxycillin per day and 6.4±5% mg/kg of clavulanate per day.

### Claim 24 (depends on 23)

The method according to claim 23 in which the dosage amount is about 90 mg/kg of amoxycillin per day and about 6.4 mg/kg of clavulanate per day.

### Claim 25 (depends on 22, 23, 24)

The method according to any one of claims 22 to 24 wherein the amoxycillin is amoxycillin trihydrate and the clavulanate is potassium clavulanate.

### Claim 26 (depends on 22)

The method according to claim 22 wherein the patient is a pediatric patient.

### Claim 27 (depends on 22)

The method according to claim 22 wherein the formulation is a tablet, or a powder or granular product for reconstitution.

### Claim 28 (depends on 22)

The method according to claim 22 wherein the formulation is a liquid aqueous syrup or suspension.

### Claim 29

A method of treating infections caused by DRSP in a patient in need thereof, which comprises administering to said patient a pharmaceutical formulation comprising a dosage amount of 90±10% mg/kg of amoxycillin per day and 6.4±10% mg/kg of clavulanate per day, said dosage amount being administered in divided doses twice daily.

### Claim 30 (depends on 29)

The method according to claim 29 in which the dosage amount is 90±5% mg/kg of amoxycillin per day and 6.4±5% mg/kg of clavulanate per day.

### Claim 31 (depends on 30)

The method according to claim 30 in which the dosage amount is about 90 mg/kg of amoxycillin per day and about 6.4 mg/kg of clavulanate per day.

### Claim 32 (depends on 29, 30, 31)

The method according to any one of claims 29 to 31 wherein the amoxycillin is amoxycillin trihydrate and the clavulanate is potassium clavulanate.

### Claim 33 (depends on 32)

The method according to claim 32 wherein the patient is a pediatric patient.

### Claim 34 (depends on 29)

The method according to claim 29 wherein the formulation is a tablet, or a powder or granular product for reconstitution.

### Claim 35 (depends on 29)

The method according to claim 29 wherein the formulation is a liquid aqueous syrup or suspension.

### Claim 36

A method of treating a Streptococcus pneumoniae infection in a patient in need thereof wherein the Streptococcus pneumoniae have a minimum inhibitory concentration value of 2 μg/ml, which comprises administering to said patient a pharmaceutical formulation comprising a dosage amount of 90±10% mg/kg of amoxycillin per day and 6.4±10% mg/kg of clavulanate per day, said dosage amount being administered in divided doses twice daily.

### Claim 37 (depends on 36)

The method according to claim 36 in which the dosage amount is 90±5% mg/kg of amoxycillin per day and 6.4±5% mg/kg of clavulanate per day.

### Claim 38 (depends on 37)

The method according to claim 37 in which the dosage amount is about 90 mg/kg of amoxycillin per day and about 6.4 mg/kg of clavulanate per day.

### Claim 39 (depends on 36, 37, 38)

The method according to any one of claims 36 to 38 wherein the amoxycillin is amoxycillin trihydrate and the clavulanate is potassium clavulanate.

### Claim 40 (depends on 39)

The method according to claim 39 wherein the patient is a pediatric patient.

### Claim 41 (depends on 39)

The method according to claim 39 wherein the formulation is a tablet, or a powder or granular product for reconstitution.

### Claim 42 (depends on 39)

The method according to claim 39 wherein the formulation is a liquid aqueous syrup or suspension.

### Claim 43

A method of treating a Streptococcus pneumoniae infection in a patient in need thereof wherein the Streptococcus pneumoniae have a minimum inhibitory concentration value of 4 μg/ml, which comprises administering to said patient a pharmaceutical formulation comprising a dosage amount of 90±10% mg/kg of amoxycillin per day and 6.4±10% mg/kg of clavulanate per day, said dosage amount being administered in divided doses twice daily.

### Claim 44 (depends on 43)

The method according to claim 43 in which the dosage amount is 90±5% mg/kg of amoxycillin per day and 6.4±5% mg/kg of clavulanate per day.

### Claim 45 (depends on 44)

The method according to claim 44 in which the dosage amount is about 90 mg/kg of amoxycillin per day and about 6.4 mg/kg of clavulanate per day.

### Claim 46 (depends on 43, 44, 45)

The method according to any one of claims 43 to 45 wherein the amoxycillin is amoxycillin trihydrate and the clavulanate is potassium clavulanate.

### Claim 47 (depends on 46)

The method according to claim 46 wherein the patient is a pediatric patient.

### Claim 48 (depends on 43)

The method according to claim 43 wherein the formulation is a tablet, or a powder or granular product for reconstitution.

### Claim 49 (depends on 43)

The method according to claim 43 wherein the formulation is a liquid aqueous syrup or suspension.

### Claim 50

A method for the empiric treatment of infections caused by bacterial infections in a human patient in need thereof, comprising the oral administration to said patient of a pharmaceutical formulation comprising amoxycillin and clavulanate in which the dosage amount is 90±10% mg/kg of amoxycillin per day and 6.4±10% mg/kg of clavulanate per day, said dosage amount being administered in divided doses twice daily.

### Claim 51 (depends on 50)

The method according to claim 50 in which the dosage amount is 90±5% mg/kg of amoxycillin per day and 6.4±5% mg/kg of clavulanate per day.

### Claim 52 (depends on 51)

The method according to claim 51 in which the dosage amount is about 90 mg/kg of amoxycillin per day and about 6.4 mg/kg of clavulanate per day.

### Claim 53 (depends on 50, 51, 52)

The method according to any one of claims 50 to 52 wherein the amoxycillin is amoxycillin trihydrate and the clavulanate is potassium clavulanate.

### Claim 54 (depends on 53)

The method according to claim 53 wherein the patient is a pediatric patient.

### Claim 55 (depends on 50)

The method according to claim 50 wherein the formulation is a tablet, or a powder or granular product for reconstitution.

### Claim 56 (depends on 50)

The method according to claim 50 wherein the formulation is a liquid aqueous syrup or suspension.
